MDX.V - MedX Health Corp

TSXV - TSXV Delayed Price. Currency in CAD
0.1550
-0.0050 (-3.12%)
At close: 2:14PM EDT
Stock chart is not supported by your current browser
Previous Close0.1600
Open0.1550
Bid0.1450 x N/A
Ask0.1500 x N/A
Day's Range0.1500 - 0.1550
52 Week Range0.0700 - 0.1600
Volume89,600
Avg. Volume176,937
Market Cap26.727M
Beta (5Y Monthly)-0.15
PE Ratio (TTM)N/A
EPS (TTM)-0.0220
Earnings DateAug. 28, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.45
  • Business Wire

    MedX Health Corp. Appoints Veteran Healthcare Industry Executive Damon Goodwin as Global Director of Sales

    MedX Health Corp. ("MedX") (TSX-V: MDX) is pleased to announce the appointment of healthcare industry executive Damon Goodwin as Global Director of Sales, effective immediately. Mr. Goodwin will play an integral part in MedX’s revenue growth by building global partnerships for MedX’s skin assessment telemedicine technology. Initially supporting the roll out and expansions in Mexico, Brazil and the USA, he will also be responsible for securing joint ventures & partnerships around the world.

  • Business Wire

    MedX Health Corp. Confirms Details of Closings of Non-Brokered Private Placements

    MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) confirms the precise specifics of the series of closings of non-brokered private placements made since January 30, 2020, announced in recent Press Releases by the Company. The following Table sets out the particulars of the dates of each closing, the number of units issued and the amount raised on each closing, together with details of Agent’s Warrants and cash commissions paid to Agents at each closing.

  • Business Wire

    MedX Health Corp. Announces Final Closing of $3 Million Non-Brokered Private Placement

    MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) announces the closing on May 13, 2020 of the final tranche of a previously announced private placement. With this closing, MedX has raised gross proceeds totalling $3,112,753 since January 30, 2020. "This marks the successful achievement, indeed over-achievement of the target, set in January 2020 to raise $3.0 million to finance the development and expansion of MedX’s complete end-to-end telehealth solution focused on Dermatology. The funding will allow MedX to hire key sales and operational personnel required to expand into new marketplaces, in particular in Latin America and the USA where the Company is anticipating rapid growth," stated Scott Spearn, CEO of MedX.

  • Business Wire

    MedX Health Corp. Announces Closing of Initial Tranches of Non-Brokered Private Placement and Announces That Due to COVID-19 Delays It Will Postpone the Release of Its Annual Financial Statements and Related Disclosures

    MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) is pleased to announce that further to the Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 25,000,000 units at $0.12 per unit ("Unit"), to raise up to $3,000,000 that was announced on March 6, 2020, the closing of two tranches of that placement have taken place, the first on April 22, and the second on April 27, 2020, for a total of 9,908,006 units, raising a total of $1,188,960. Closings of further tranches of this non-brokered placement are anticipated during the course of the coming days. Each Unit is comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of $0.20, exercisable for a period of two years from the date of issue. The securities issued on April 22 and April 27, 2020, will be restricted from trading for four months from their respective dates of issue.

  • Business Wire

    MedX Health Corp. Announces Proposed Extension of Non-Brokered Private Placement Offering

    MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) announced today that, subject to acceptance by the TSX-V the ultimate Closing Date for the non-brokered Private Placement of up to $2.5 million, which was previously announced on March 6, 2020, will be extended by up to 30 days. The Company has already received Conditional Acceptance for the placement from the TSX-V, but closings have been delayed primarily as a result of Government-imposed restrictions in response to the COVID-19 Pandemic. The proposed placement, to accredited investors, is for the placement of up to 20,833,333 units at $0.12 per unit ("Unit"). Each Unit will be comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of $0.20, exercisable for a period of two years from the date of issue. Closing of the Placement, which will take place in tranches, will be subject to receipt of subscriptions and a number of other conditions, including without limitation the receipt of all relevant regulatory and Stock Exchange approvals or acceptances. Qualified Agents may receive commissions in respect of subscriptions introduced by them by way of cash equal to 8% of funds so introduced, and issuance of agent’s warrants ("Agent’s Warrant(s)") equal in number to 8% of the number of units so subscribed for. Each Agent’s Warrant, which is non-transferable, will be exercisable to acquire one Unit at $0.12 per Unit, at any time during the period of two years following the Closing.

  • Business Wire

    MedX Receives MDSAP Certification, The Highest Regulatory Standard in the Medical Device Manufacturing Industry

    MedX Health Corp. ("MedX") (TSX-V: MDX) a leading medical device and software company focused on skin assessment in identifying suspicious moles and lesions by utilizing its SIAscopy optical scanning technology coupled with its SIAscopy on DermSecure™ telemedicine platform, is pleased to announce that it has achieved a recommendation for continued certification on successful completion of an audit under the Medical Device Single Audit Program ("MDSAP").

  • Business Wire

    MedX Receives Regulatory Approval in Brazil

    MedX Health Corp. ("MedX") (TSX-V: MDX) announces that it has received regulatory approval to market and sell its SIAscopy on DermSecure TM skin assessment platform in Brazil. "MedX has worked seamlessly with its Brazilian distribution partners, MedX Brasil and Oneway Diagnostica to ensure we were able to complete this important certification from ANVISA, Brazil’s regulatory authority," commented Scott Spearn, President & CEO of MedX. "We had the support of the Brazilian Dermatological community in this process, and we are very appreciative of the efforts and professionalism of our partners in achieving this milestone."

  • Business Wire

    MedX Health Corp. Announces Closing of Non-Brokered Private Placement and Debt Settlement and Announces a New Non-Brokered Private Placement Offering

    MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) is pleased to announce that further to the Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 25,000,000 units at $0.12 per unit ("Unit"), to raise up to $3,000,000 that was announced on January 30, 2020, and the closing of the first tranche of that placement, of 1,485,000 units, raising $178,200, on January 30, 2020, two further closings have taken place, on March 4, 2020, of 7,459,139 units, raising $895,096, and on March 5, 2020, of 2,000,000 units, raising $240,000. Each Unit is comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of $0.20, exercisable for a period of two years from the date of issue. The securities issued on January 30, 2020, March 4, 2020 and March 5, 2020, will be restricted from trading for four months from their respective dates of issue.

  • Business Wire

    MedX Health Corp. Announces Proposed Debt Settlement

    MedX Health Corp. (TSX-V:MDX), announces that it has entered into an agreement to settle $372,071 of debt owed to an arm’s length trade creditor, subject to all relevant consents and approvals. Under the Debt Settlement Agreement, $372,071 of trade debt will be settled by the issuance of 3,103,878 units ("Unit(s)") at a price of $0.12 per Unit. Each Unit comprises one fully paid common share and one share purchase warrant, exercisable for a period of two (2) years from the date of issue, to acquire a further common share at the price of $0.20. Regulatory and other consents will include acceptance from the TSX Venture Exchange.

  • Those Who Purchased MedX Health (CVE:MDX) Shares Three Years Ago Have A 59% Loss To Show For It
    Simply Wall St.

    Those Who Purchased MedX Health (CVE:MDX) Shares Three Years Ago Have A 59% Loss To Show For It

    Investing in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of...